Established in 2001 and headquartered in Dunedin, New Zealand, Pacific Edge Limited is a cancer diagnostics company dedicated to inventing, developing, and commercializing diagnostic and prognostic tools. These tools are designed for the early detection and effective management of various cancers, with the company's reach extending across New Zealand, the United States, Australia, and Singapore. Its operations are divided into two main segments: Commercial and Research. The company's primary offering is Cxbladder, a comprehensive series of genomic urine tests used for the identification and ongoing care of bladder cancer. Pacific Edge is actively advancing several additional products within the Cxbladder portfolio: Cxbladder Resolve, intended to identify patients likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, which helps pinpoint haematuria patients with a low probability of bladder cancer; Cxbladder Detect, for the non-invasive screening of bladder and other urinary tract cancers; and Cxbladder Monitor, enabling urologists to track the recurrence of bladder cancer in patients. Beyond bladder cancer, the company is also developing Cxcolorectal, a prognostic gene signature for individuals diagnosed with stage II or stage III colorectal cancers, and has other products in its pipeline targeting bladder, gastric, colorectal, endometrial cancers, and melanoma.
—
Established in 2001 and headquartered in Dunedin, New Zealand, Pacific Edge Limited is a cancer diagnostics company dedicated to inventing, developing, and commercializing diagnostic and prognostic tools. These tools are designed for the early detection and effective management of various cancers, with the company's reach extending across New Zealand, the United States, Australia, and Singapore. Its operations are divided into two main segments: Commercial and Research. The company's primary offering is Cxbladder, a comprehensive series of genomic urine tests used for the identification and ongoing care of bladder cancer. Pacific Edge is actively advancing several additional products within the Cxbladder portfolio: Cxbladder Resolve, intended to identify patients likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, which helps pinpoint haematuria patients with a low probability of bladder cancer; Cxbladder Detect, for the non-invasive screening of bladder and other urinary tract cancers; and Cxbladder Monitor, enabling urologists to track the recurrence of bladder cancer in patients. Beyond bladder cancer, the company is also developing Cxcolorectal, a prognostic gene signature for individuals diagnosed with stage II or stage III colorectal cancers, and has other products in its pipeline targeting bladder, gastric, colorectal, endometrial cancers, and melanoma.
—
Daily adjusted close
Established in 2001 and headquartered in Dunedin, New Zealand, Pacific Edge Limited is a cancer diagnostics company dedicated to inventing, developing, and commercializing diagnostic and prognostic tools. These tools are designed for the early detection and effective management of various cancers, with the company's reach extending across New Zealand, the United States, Australia, and Singapore. Its operations are divided into two main segments: Commercial and Research. The company's primary offering is Cxbladder, a comprehensive series of genomic urine tests used for the identification and ongoing care of bladder cancer. Pacific Edge is actively advancing several additional products within the Cxbladder portfolio: Cxbladder Resolve, intended to identify patients likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, which helps pinpoint haematuria patients with a low probability of bladder cancer; Cxbladder Detect, for the non-invasive screening of bladder and other urinary tract cancers; and Cxbladder Monitor, enabling urologists to track the recurrence of bladder cancer in patients. Beyond bladder cancer, the company is also developing Cxcolorectal, a prognostic gene signature for individuals diagnosed with stage II or stage III colorectal cancers, and has other products in its pipeline targeting bladder, gastric, colorectal, endometrial cancers, and melanoma.